Gyre Therapeutics, Inc.
GYRE
$7.01
-$0.64-8.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -58.40% | 107.49% | 104.84% | 108.27% | 113.00% |
| Total Depreciation and Amortization | 58.69% | 66.55% | 83.95% | 37.41% | 42.55% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 111.59% | -92.62% | -93.77% | -94.24% | -94.51% |
| Change in Net Operating Assets | 20.10% | -48.54% | -60.53% | -676.24% | -236.70% |
| Cash from Operations | 127.74% | 56.52% | -88.88% | -136.24% | -114.06% |
| Capital Expenditure | 48.60% | 79.15% | 83.19% | 68.51% | 72.82% |
| Sale of Property, Plant, and Equipment | -92.52% | -63.49% | -80.95% | -50.70% | -39.61% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 103.82% | 79.60% | 76.06% | 50.70% | -6.94% |
| Cash from Investing | 97.62% | 73.85% | 72.05% | 44.67% | -0.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 880.48% | 1,956.47% | 2,815.54% | 423.56% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -177.43% | -997.04% | -1,764.71% | -- | -- |
| Cash from Financing | 1,059.75% | 587.85% | 653.86% | -11.72% | -15.92% |
| Foreign Exchange rate Adjustments | 225.64% | -118.31% | -117.99% | 67.46% | 8.39% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 216.41% | 340.24% | 367.32% | -998.23% | -360.33% |